US 2010/0137239 A1Published application

Gemcitabine combination therapy

AssigneeGloucester Pharmaceuticals, Inc.

InventorsWilliam McCulloch, Mitchell Keegan

Life of this patent

Estimating the term…

Abstract

The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and gemcitabine.

Claims9

Dependent claims

A method comprising steps of:

administering to a subject suffering from or susceptible to a cell proliferative disorder, combination therapy of a DAC inhibitor and gemcitabine.

Dependencies are inferred from the claim text.

Facts

Application: 12/298,265Filed 13 Apr 2007
Priority: 24 Apr 2006
Published: 3 Jun 2010
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 38/12
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins…
A61K 31/7068
Containing condensed or non-condensed pyrimidines: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 38/15
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: depsipeptides; Derivatives thereof
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…

Family

Application60/794,599Us provisional application · filed 24 Apr 2006
US 2010/0137239 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results